Medy-Tox Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
14,304
43,628
42,293
59,231
73,167
Depreciation, Depletion & Amortization
1,871
2,858
3,845
4,749
8,212
Other Funds
329
1,545
1,455
1,239
1,376
Funds from Operations
15,676
51,576
45,203
69,778
95,892
Changes in Working Capital
1,602
54,903
21,944
16,334
38,097
Net Operating Cash Flow
17,278
106,479
23,259
53,444
57,794
Capital Expenditures
18,605
20,784
33,813
144,671
46,708
Sale of Fixed Assets & Businesses
-
1
-
29
4,985
Purchase/Sale of Investments
11,758
63,495
26,234
30,612
1,211
Net Investing Cash Flow
6,860
84,945
8,498
114,519
41,474
Cash Dividends Paid - Total
2,719
8,113
8,543
9,595
11,119
Issuance/Reduction of Debt, Net
1,442
212
16,208
74,273
18,643
Net Financing Cash Flow
6,847
20,759
6,920
50,093
5,343
Net Change in Cash
3,558
651
22,109
10,961
10,587
Free Cash Flow
725
89,843
6,827
83,055
19,751
Other Sources
-
-
149
1,255
1,730
Change in Capital Stock
5,900
14,402
2,199
15,824
14,243
Exchange Rate Effect
12
125
427
21
390
Other Uses
13
667
1,068
1,743
2,692

About Medy-Tox

View Profile
Address
78 Gangni 1-gil
Cheongju-si NC 28126
Korea, Republic Of
Employees -
Website http://www.medy-tox.co.kr
Updated 09/14/2018
Medy-Tox, Inc. engages in the manufacture and sale of biopharmaceutical products. Its products include botulinum toxin, hyaluronic acid filler, medical devices, toxin detection kit and antitoxin therapeutics. The company was founded on May 2, 2000 and is headquartered in Cheongju-si, South Korea.